240 related articles for article (PubMed ID: 28088639)
1. Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pylori.
Seabra CL; Nunes C; Gomez-Lazaro M; Correia M; Machado JC; Gonçalves IC; Reis CA; Reis S; Martins MCL
Int J Pharm; 2017 Mar; 519(1-2):128-137. PubMed ID: 28088639
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticles to counteract gastric infection without affecting gut microbiota.
Seabra CL; Nunes C; Brás M; Gomez-Lazaro M; Reis CA; Gonçalves IC; Reis S; Martins MCL
Eur J Pharm Biopharm; 2018 Jun; 127():378-386. PubMed ID: 29524597
[TBL] [Abstract][Full Text] [Related]
3. Helicobacter pylori biofilms are disrupted by nanostructured lipid carriers: A path to eradication?
Pinho AS; Seabra CL; Nunes C; Reis S; L Martins MC; Parreira P
J Control Release; 2022 Aug; 348():489-498. PubMed ID: 35654169
[TBL] [Abstract][Full Text] [Related]
4. Physical and chemical stability of nanostructured lipid drug carriers (NLC) based on natural lipids from Baikal region (Siberia, Russia).
Averina ES; Müller RH; Popov DV; Radnaeva LD
Pharmazie; 2011 May; 66(5):348-56. PubMed ID: 21699068
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
6. Docosahexaenoic Acid-Loaded Nanostructured Lipid Carriers for the Treatment of Peri-Implantitis in Rats.
Li Z; Yin Z; Li B; He J; Liu Y; Zhang N; Li X; Cai Q; Meng W
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768193
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of hesperidin and clarithromycin in a nanostructured lipid carrier for the eradication of Helicobacter pylori in vitro.
Sharaf M; Arif M; Khan S; Abdalla M; Shabana S; Chi Z; Liu C
Bioorg Chem; 2021 Jul; 112():104896. PubMed ID: 33901764
[TBL] [Abstract][Full Text] [Related]
8. Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization.
Correia M; Michel V; Matos AA; Carvalho P; Oliveira MJ; Ferreira RM; Dillies MA; Huerre M; Seruca R; Figueiredo C; Machado JC; Touati E
PLoS One; 2012; 7(4):e35072. PubMed ID: 22529974
[TBL] [Abstract][Full Text] [Related]
9. Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model.
Fernandes RS; Silva JO; Mussi SV; Lopes SCA; Leite EA; Cassali GD; Cardoso VN; Townsend DM; Colletti PM; Ferreira LAM; Rubello D; de Barros ALB
Mol Imaging Biol; 2018 Jun; 20(3):437-447. PubMed ID: 29043471
[TBL] [Abstract][Full Text] [Related]
10. Sucupira Oil-Loaded Nanostructured Lipid Carriers (NLC): Lipid Screening, Factorial Design, Release Profile, and Cytotoxicity.
Vieira R; Severino P; Nalone LA; Souto SB; Silva AM; Lucarini M; Durazzo A; Santini A; Souto EB
Molecules; 2020 Feb; 25(3):. PubMed ID: 32041134
[TBL] [Abstract][Full Text] [Related]
11. Helicobacter pylori's cholesterol uptake impacts resistance to docosahexaenoic acid.
Correia M; Casal S; Vinagre J; Seruca R; Figueiredo C; Touati E; Machado JC
Int J Med Microbiol; 2014 May; 304(3-4):314-20. PubMed ID: 24447914
[TBL] [Abstract][Full Text] [Related]
12. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery.
Gonzalez-Mira E; Egea MA; Souto EB; Calpena AC; García ML
Nanotechnology; 2011 Jan; 22(4):045101. PubMed ID: 21169662
[TBL] [Abstract][Full Text] [Related]
13. Engineering resveratrol-loaded chitosan nanoparticles for potential use against Helicobacter pylori infection.
Spósito L; Fonseca D; Gonçalves Carvalho S; Sábio RM; Marena GD; Bauab TM; Bagliotti Meneguin A; Parreira P; L Martins MC; Chorilli M
Eur J Pharm Biopharm; 2024 Jun; 199():114280. PubMed ID: 38588828
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus-loaded nanostructured lipid carriers for oral delivery - Optimization of production and characterization.
Khan S; Shaharyar M; Fazil M; Baboota S; Ali J
Eur J Pharm Biopharm; 2016 Nov; 108():277-288. PubMed ID: 27449630
[TBL] [Abstract][Full Text] [Related]
15. Performance of β-carotene-loaded nanostructured lipid carriers under dynamic in vitro digestion system: Influence of the emulsifier type.
Lüdtke FL; Fernandes JM; Gonçalves RFS; Martins JT; Berni P; Ribeiro APB; Vicente AA; Pinheiro AC
J Food Sci; 2024 Jun; 89(6):3290-3305. PubMed ID: 38767864
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of 4-dedimethylamino sancycline (CMT-3) loaded nanostructured lipid carrier (CMT-3/NLC) formulations.
Yang X; Zhao L; Almasy L; Garamus VM; Zou A; Willumeit R; Fan S
Int J Pharm; 2013 Jun; 450(1-2):225-34. PubMed ID: 23608200
[TBL] [Abstract][Full Text] [Related]
17. Docosahexaenoic acid inhibits Helicobacter pylori-induced STAT3 phosphorylation through activation of PPARγ.
Ji HG; Piao JY; Kim SJ; Kim DH; Lee HN; Na HK; Surh YJ
Mol Nutr Food Res; 2016 Jun; 60(6):1448-57. PubMed ID: 27079734
[TBL] [Abstract][Full Text] [Related]
18. Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization.
Islan GA; Tornello PC; Abraham GA; Duran N; Castro GR
Colloids Surf B Biointerfaces; 2016 Jul; 143():168-176. PubMed ID: 27003467
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of nanostructured lipid carriers loaded traditional Chinese medicine, zedoary turmeric oil.
Zhao XL; Yang CR; Yang KL; Li KX; Hu HY; Chen DW
Drug Dev Ind Pharm; 2010 Jul; 36(7):773-80. PubMed ID: 20136496
[TBL] [Abstract][Full Text] [Related]
20. Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori.
Jain SK; Haider T; Kumar A; Jain A
AAPS PharmSciTech; 2016 Oct; 17(5):1131-40. PubMed ID: 26566630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
